ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Denver-based RheumaGen has raised $15 million in series A financing to develop gene therapies for autoimmune disease. The start-up’s lead drug candidate precisely edits a dysfunctional human leukocyte antigen (HLA) gene in humans to treat refractory rheumatoid arthritis (RA). HLA genes are an important component of the human immune system, and mutations in them can cause autoimmune disease. The drug is meant to be a one-time curative treatment for RA; the company plans to begin Phase 1 clinical trials in 2026.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X